Hematology (all articles)
Clinical Cancer Advances 2021: ASCO’s Report on Progress Against Cancer
7 Feb, 2021 | 20:45h | UTCCommentary: ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
3 Feb, 2021 | 01:07h | UTCASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – Blood
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
Preliminary study shows sitagliptin may prevent acute Graft-versus-Host Disease
26 Jan, 2021 | 00:35h | UTCDipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Sitagliptin promising addition for preventing acute GVHD – HealthDay
Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis
25 Jan, 2021 | 01:15h | UTCLong-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)
[Press Release – Not Published Yet] Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients
25 Jan, 2021 | 01:42h | UTC
Cohort study: Recipients of hematopoietic stem-cell transplantation who develop COVID-19 have poor overall survival
21 Jan, 2021 | 01:18h | UTC
Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb
21 Jan, 2021 | 01:10h | UTCSummary: Thrombolysis for treatment of acute deep vein thrombosis – Cochrane Library
Meta-Analysis: Low-intensity warfarin may be an option for patients under 65 years of age with non-valvular atrial fibrillation
21 Jan, 2021 | 00:57h | UTCMeta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation – The American Journal of Cardiology (link to abstract – $ for full-text)
[Abstract Only] Meta-analysis: Myelodysplastic syndrome and acute myeloid leukemia in patients treated with PARP inhibitors
21 Jan, 2021 | 00:37h | UTCMyelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database – The Lancet Haematology (link to abstract – $ for full-text)
Commentary on Twitter
NEW research: a safety meta-analysis of RCTs and a retrospective study of the WHO pharmacovigilance database shows an increased risk of myelodysplastic syndrome and acute myeloid leukaemia in patients treated w/ PARP inhibitors #MDSsm #leusm https://t.co/evYF1ozg6c
— The Lancet Haematology (@TheLancetHaem) December 21, 2020
Randomized trial: Dabigatran non-inferior to standard of care for children with acute venous thromboembolism
21 Jan, 2021 | 00:35h | UTCDabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial – The Lancet Haematology (link to abstract – $ for full-text)
RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19
17 Jan, 2021 | 22:26h | UTCCommentary: Covid: ‘Convalescent plasma no benefit to hospital patients’ – BBC
Observational study: Among patients hospitalized with Covid-19 not receiving mechanical ventilation, transfusion of plasma with higher anti–SARS-CoV-2 IgG antibody levels is linked to lower risk of death than transfusion of plasma with lower antibody levels
15 Jan, 2021 | 08:59h | UTCEditorial: (A Little) Clarity on Convalescent Plasma for Covid-19 – New England Journal of Medicine
Commentaries: Expert reaction to study looking at convalescent plasma antibody levels and risk of death from COVID-19 – Science Media Centre AND Antibody-rich convalescent plasma may lower risk of COVID death – CIDRAP
Opinion: RCTs don’t justify using convalescent plasma or antibody cocktails
15 Jan, 2021 | 08:58h | UTCRCTs don’t justify using convalescent plasma or antibody cocktails – PulmCrit
Randomized trial: Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma
15 Jan, 2021 | 08:12h | UTCOnce-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary: Triplet therapy slows refractory multiple myeloma – MedicalXpress
Systematic review: Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
13 Jan, 2021 | 01:37h | UTC
Blood plasma treatment has limited effect for sickest COVID-19 patients
12 Jan, 2021 | 02:07h | UTCBlood plasma treatment has limited effect for sickest COVID-19 patients – Imperial College London
See also: Expert reaction to REMAP-CAP recruitment of severely ill COVID-19 patients into convalescent plasma trial being paused after initial analysis suggested it did not improve outcomes – Science Media Centre AND Trial of COVID-19 blood plasma finds no benefit in severely ill patients – Reuters
Randomized trial: Plasma therapy administered early is beneficial in high-risk elderly patients
12 Jan, 2021 | 02:05h | UTCCommentaries: Early convalescent plasma may lower risk of severe COVID in seniors – CIDRAP AND Covid-19: Early Plasma Treatment Improved Outcomes in Older Patients – Physician’s Weekly
Commentaries on Twitter
Just published @NEJM: A small, placebo-controlled randomized trial (N=160) of high IgG titer convalescent plasma administered early (within 72 hrs) for mild covid-19 to older adults (median age >70) shows benefit https://t.co/dhyFH4OwpH pic.twitter.com/14lMBBofUh
— Eric Topol (@EricTopol) January 6, 2021
Early convalescent plasma may lower risk of severe COVID in seniors@NEJM study finds that 16% of those treated with high-titer convalescent therapy developed severe #COVID19, compared with 31% in the placebo grouphttps://t.co/7hqCXsNHDM pic.twitter.com/dZDUwcjxUh
— CIDRAP (@CIDRAP) January 6, 2021
ACC Consensus: Anticoagulation and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing PCI or with atherosclerotic cardiovascular disease
12 Jan, 2021 | 01:50h | UTCCommentaries: ACC Issues New Guidance Around Antithrombotic Choices in A-fib, VTE – TCTMD AND ACC Issues Clinical Guidance For Antithrombotic Therapy in Patients With AFib or VTE Undergoing PCI or With ASCVD – American College of Cardiology
Commentary on Twitter
ICYMI: @ACCinTouch released clinical guidance for antithrombotic therapy in pts w/ #AFib/#VTE undergoing PCI or w/ #ASCVD. Doc aims to serve as a framework for decision-making among pts requiring concomitant use of an anticoagulant & antiplatelet therapy. https://t.co/PqinRIvLY9 pic.twitter.com/prbnbBPG5L
— JACC Journals (@JACCJournals) December 29, 2020
[Press release – results not published yet] International trials of blood thinners in critically ill COVID-19 patients pause due to futility
10 Jan, 2021 | 20:44h | UTC
Commentary on Twitter
The 3 largest RCTs of therapeutic #anticoagulation for #COVID19 pts in the ICU have ALL been stopped early for futility. (@remap_cap @ATTACC_COVID & #ACTIV4)
Nothing published yet, but given the large n of these RCTs, I'm increasingly skeptical about anticoagulation in COVID19. pic.twitter.com/RrLSoOsp3v
— Nick Mark MD (@nickmmark) December 22, 2020
Randomized trial: In extremely-low-birth-weight infants, a higher hemoglobin threshold for red-cell transfusion does not improve outcomes
10 Jan, 2021 | 20:36h | UTCHigher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Higher red cell transfusion threshold offers no advantage for treating preterm infants – NIH News Releases
Case series: Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer
2 Dec, 2020 | 07:31h | UTC
NICE COVID-19 guideline: Prevention of thromboembolism in patients with COVID-19. “For patients who are having advanced respiratory support: consider increasing pharmacological VTE prophylaxis to an intermediate dose”
1 Dec, 2020 | 08:19h | UTC
Randomized trial: Intravenous iron is superior to oral iron for the treatment of anemia in women after childbirth in a low-income setting
27 Nov, 2020 | 08:41h | UTC
Commentary on Twitter
In a randomised trial in Tanzania, intravenous ferric carboxymaltose proved safe and better than oral iron at achieving haemoglobin normalisation (>115 g/L) at 6 weeks after childbirth in women with iron deficiency anaemia https://t.co/F5sau45dwL pic.twitter.com/qqa8cGbMqZ
— The Lancet Global Health (@LancetGH) November 25, 2020
Randomized trial: Convalescent Plasma does not improve clinical status or overall mortality in severe Covid-19 pneumonia
25 Nov, 2020 | 09:17h | UTCCommentary: New trial of convalescent plasma for covid-19 falls flat, another setback for hyped treatment – Brief19
Commentary on Twitter
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia @NEJM A well conducted RCT shows no significant differences in clinical status or overall mortality between patients treated with CP and those who received placebo. https://t.co/C6NylbO2At
— Carlos del Rio (@CarlosdelRio7) November 24, 2020